1
|
Affiliation(s)
- Edgar Lichstein
- Department of Medicine, Maimonides Medical Center and Albert Einstein College of Medicine, New York, New York.
| | - Abhishek Sharma
- Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
2
|
Alliu SE, Adejumo A, Durojaiye M, Adegbala O, Ajayi T, Onyeakusi N, Wolf L, Kamholz S, Shani J, Lichstein E. Abstract 493: Correlation Between Cannabis Use and the Prevalence of Cerebrovascular Disease (Cva); Analysis From the National Inpatient Sample (NIS) 2012-2014. Arterioscler Thromb Vasc Biol 2017. [DOI: 10.1161/atvb.37.suppl_1.493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
With increasing legalization of cannabis, there is a growing number of cannabis users in the US. Cannabidiol - a component of cannabis with no psychoactive or cognitive effect has been proven in animal models to have vasodilatory and anti-inflammatory effect on the blood vessels. However, in clinical literature, the association between cerebrovascular accident (CVA) and cannabis remains inconclusive.
Objective:
To examine if there is a difference in the prevalence of CVA among patients who use cannabis and non-users.
Methods:
We identified patients > 18 years (N=12,114,360) from the 2012 -2014 National Inpatient Sample database. Using the ICD-9 code, we categorized patients using cannabis (non-dependent and dependent users) and non-users. Our outcome of interest was prevalence of CVA in this population. Logistic regression analysis was performed to assess the association between cannabis use and CVA. Using multivariate regression model, we adjusted for known confounders of CVA; age, gender, race, insurance type, socioeconomic status, tobacco use, cocaine use, alcohol abuse, amphetamine use, hyperlipidemia, diabetes, hypertension, renal failure, prior history of CVA and family history of CVA.
Results:
From our study sample (12,114,360 hospitalized patients), 2.1% (253,752) had a diagnosis of CVA, 1.48% (179,576) were non-dependent cannabis users and 0.21% (25,968) dependent users. Among hospitalized patient, non-dependent cannabis use was associated with an 8% increased odds of CVA (AOR 1.08 [1.03-1.13]) compared to non-users. However, dependent cannabis use was associated with a 60% decreased odds of CVA (AOR 0.40 [0.31-0.49]) compared to non-users. Also, In-group comparison shows a 60% decreased odds of CVA among dependent cannabis users (AOR 0.36[0.29-0.46]) compared to non-dependent cannabis users.
Conclusions:
Non-dependent cannabis use was associated with a slightly increased odd of CVA while dependent cannabis use was independently protective against CVA. Our study used the largest repository of clinical information to explore this association, however we recommend more clinical study to explore this correlation in other to maximize the pharmacological benefit of cannabidiol in cannabis for the prevention of CVA.
Collapse
Affiliation(s)
| | | | | | | | - Tokunbo Ajayi
- Johns Hopkins Medicine, Howard County General Hosp, Columbia MD, Columbia, MD
| | | | | | | | | | | |
Collapse
|
3
|
Adegbala OM, Akinjero A, Alliu S, Adejumo AC, Akintoye E, Otuada D, Ajayi T, Onyeakusi N, Edo-Osagie E, Durojaiye M, Lichstein E, Akinyemiju T. Abstract 491: Racial Disparities in the Trends of Acute Myocardial Infarction Outcomes Among Medicaid Patients, 2007-2011. Arterioscler Thromb Vasc Biol 2017. [DOI: 10.1161/atvb.37.suppl_1.491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Although, in-hospital mortality from acute myocardial infarction (AMI) have declined in the United States recently, there is a gap in knowledge regarding racial differences in this trend. We sought to evaluate the effect of race on the trends in outcomes after Acute Myocardial Infarction among Medicaid patients in a nationwide cohort from 2007-2011
Methods:
We extracted data from the Nationwide Inpatient Sample (NIS) for all hospitalizations between 2007 and 2011 for Medicaid patients aged 45 years or older with principal diagnosis of AMI using ICD-9-CM codes. Primary outcome of this study was all cause in-hospital mortality. We then stratified hospitalizations by racial groups; Whites, African Americans and Hispanics, and assessed the time trends of in-hospital mortality before and after multivariate analysis.
Results:
The overall mortality from AMI among Medicaid patients declined during the study period (8.80% in 2007 to 7.46% in 2011). In the adjusted models, compared to 2007, in-hospital mortality from AMI for Medicaid patients decreased across the 3 racial groups; Whites (aOR= 0.88, CI=0.70-0.99), African Americans (aOR=0.76, CI=0.57-1.01), Hispanics (aOR=0.87, CI=0.66-1.25). While the length of hospital stay declined significantly among African American and Hispanic with 2 days and 1.76 days decline respectively, the length of stay remained unchanged for Whites. There was non-significant increase in the incidence of stroke across the various racial groups; Whites (aOR= 1.23, CI=0.90 -1.69), African Americans (aOR=1.10, CI=0.73 -1.64), Hispanics (aOR=1.03, CI=0.68-1.55) when compared to 2007.
Conclusion:
In this study, we found that in-hospital mortality from AMI among Medicaid patients have declined across the racial groups. However, while the length of stay following AMI declined for African Americans and Hispanics with Medicaid insurance, it has remained unchanged for Whites. Future studies are necessary to identify determinants of these significant racial disparities in outcomes for AMI.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Tokunbo Ajayi
- John Hopkins Medicine, Howard County General Hosp, DC
| | | | | | | | | | | |
Collapse
|
4
|
Adejumo AC, Alliu S, Ajayi TO, Oluwole AM, Onyeakusi N, Adejumo K, Durojaiye M, Bob-manuel T, Almaddah N, Lichstein E. Abstract 100: Prevalence of Peripheral Vascular Disease Among Patients Using Cannabis, an Analysis of the 2014 National Inpatient Sample data. Circ Cardiovasc Qual Outcomes 2017. [DOI: 10.1161/circoutcomes.10.suppl_3.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Despite being illegal in most countries, cannabis is highly utilised by a growing number of individuals for recreational purposes worldwide. With its increasing legalisation in many states across the United States, the effects of cannabis on different body systems are expected to rise. Its association with peripheral vascular disease (PVD) remains ambiguous.
Objective:
To examine if there is a difference in prevalence of PVD amongst patients who use cannabis when compared to non-users.
Methods:
Using the 2014 National Inpatient Sample database (N=7,071,762), we identified patients with and without a diagnosis of PVD. We also identified patients using cannabis (nondependent and dependent users) and non-users. We performed the univariate and bivariate analysis. After we had composed the crude models, we adjusted for every known risk factor for PVD. These factors included age, gender, tobacco, hypercholesterolemia, coronary artery disease (CAD), cerebrovascular vessel disease (CVD), hypertension, diabetes, renal failure, alcohol, obesity, race, insurance type, average income at the location of residence, and family history of PVD/CVD/CAD.
Results:
In our total 7,071,762 sample, 98.27% (6,949,339) are non-users, 1.54% (108,910) are nondependent users and 0.19% (13,513) are dependent users. About 3.75% (264,920) of the patients had a diagnosis of PVD versus 96.25% (6,806,842) without a diagnosis of PVD. The odds of PVD is 20% less among nondependent users when compared to nonusers (AOR 0.80[0.76-0.85]). Furthermore, dependent users have a 55% reduced odds of developing PVD when compared to nonusers (AOR 0.45[0.35-0.57]) showing a dose-response relationship. The in-group comparison showed that dependent users were 44% less likely to have PVD when compared to non-dependent users (AOR: 0.56[0.44-0.72]). Overall, the odds of PVD remain significantly high among patients who uses tobacco (AOR 1.97 [1.95-1.99]), diabetes (AOR 1.54 [1.53-1.55]), hypercholesterolemia (AOR 1.46 [1.45-1.47]), family history of PVD/CVD/CAD (AOR 1.03 [1.01-1.05]), personal history of CAD (AOR 2.55 [2.53-2.57]).
Conclusions:
Cannabis is an independent protective factor against PVD. Molecular biology evidence shows that cannabis contains various bioactive agents. Beta-caryophyllene (out of many) preferentially binds to CB-2 receptors on immune cells causing an anti-inflammatory response. We believe that more molecular studies targeting such receptors or isolating such anti-inflammatory compounds in cannabis might be useful in the treatment of vascular disease.
Collapse
Affiliation(s)
| | | | - Tokunbo O Ajayi
- Johns Hopkins Medicine, Howard County General Hosp, Columbia, MD
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Alliu SE, Adejumo A, Durojaiye M, Emmanuel A, Wolf L, Lichstein E, Hecht M, Stephan K, Adegbala O, Onyeakusi N, Ajayi T. Abstract 072: Impact of Chronic Diabetes on Periprocedural Outcomes Among Patient With Atrial Fibrillation and Flutter Who Underwent Radiofrequency Catheter Ablation Therapy (RFA). Report From the NIS 2014. Circ Cardiovasc Qual Outcomes 2017. [DOI: 10.1161/circoutcomes.10.suppl_3.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Diabetes has been associated with complications and poor perioperative outcomes. In Radiofrequency catheter ablation - therapy of choice for drug refractory atrial fibrillation and flutter, association between diabetes and procedural complications are less documented.
Objectives:
To examine if there is a difference in perioperative complications in patients with chronic diabetes who underwent RFA for atrial fibrillation/flutter when compared with non-diabetics.
Methods:
We selected patients > 45 years from the National Inpatient Survey data 2014. We identified 8356 patients (69.6 ± 9.1yrs) who underwent catheter ablation. Logistic regression analyses were performed to investigate the difference in perioperative complications (hemorrhage, cardiac perforation, cardiac complications, respiratory complications, peripheral vascular complications, stroke and in-hospital mortality) between diabetics and non-diabetics. All models were adjusted for age, gender, race, residential income, insurance, co-morbidities, hospital bed size, hospital location/teaching status, hospital region, length of stay and median household income.
Results:
Among our selected 8356 patients, 5777(69.1%) were non-diabetics, 2203(26.4%) had uncomplicated diabetes and 376 (4.5%) complicated diabetes. Overall there were 634 events (240 hemorrhages, 56 perforations, 163 cardiac complications, 43 respiratory complications, 12 strokes, 40 peripheral vascular complications and 80 in-hospital death. Rates of complications were the same among diabetes and non-diabetics. In the multivariate models, the odds of complications remain statistically non-significant across all the groups. However, among all the patients who underwent RFA, there is an increased odds of hemorrhage among patients with Medicare insurance versus private insurance (OR 1.73 95%CI 1.11-2.70), peripheral vascular complications among hospitals in the south (OR 3.35 95%CI 1.30-9.62), respiratory complications among patients with CHF (4.60 95%CI 1.68-12.60), death among patients with renal failure (OR 2.22 95%CI 1.32-3.73) and hospitals in the south (2.55 95% CI 1.08-6.0) and west (OR 3.23 95%CI 1.25-8.3) compared to the northeast. Odds of stroke were less among both urban non-teaching (OR 0.02 95%CI 0.01 - 0.34) and teaching hospital (OR 0.05 95%CI 0.01-0.36) when compared to rural hospital.
Conclusions:
RFA has a similar procedural safety in diabetics when compared to non-diabetic patients. It remains a safe procedure in diabetics with drug-refractory atrial fibrillation and flutter. Renal failure, CHF, type of Insurance, hospital location and teaching status are predictors of complications after RFA.
Collapse
|
6
|
Mahajan N, Hollander G, Malik B, Temple B, Thekkoott D, Abrol S, Schulhoff N, Ghosh J, Shani J, Lichstein E. Isolated and Significant Left Main Coronary Artery Disease: Demographics, Hemodynamics and Angiographic Features. Angiology 2016; 57:464-77. [PMID: 17022383 DOI: 10.1177/0003319706290740] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Left main coronary artery disease carries a poor prognosis. The etiology of isolated and significant left main coronary artery (ILMCA) disease is not well understood. Studies so far were limited by small numbers. The authors identified 46 patients with ILMCA disease from their database over 10 years (group I) and compared them with 83 consecutive patients undergoing catheterization (group II). They also compared patients with ostial vs distal ILMCA disease. Group I represented 0.1% of catheterization patients. The demographic profile and atherosclerotic risk factor profile of the 2 groups as well as ostial and distal ILMCA disease were compared. This is the largest study of ILMCA disease. Risk factors for atherosclerosis were commonly seen. Nonatherosclerotic causes of ILMCA disease were not seen. This study suggests coronary atherosclerosis as the predominant cause of ILMCA disease. ILMCA disease is more common in women. Diabetes is more commonly associated with distal ILMCA lesion. There is a trend suggesting that ostial ILMCA lesion is more common in smokers and women.
Collapse
Affiliation(s)
- Nitin Mahajan
- Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Kwan C, Lin YS, Homel P, Rojas M, Shetty V, Lichstein E. Barriers to Care in Elderly Chinese Adults with Heart Disease. J Am Geriatr Soc 2016; 64:e41-2. [PMID: 27562949 DOI: 10.1111/jgs.14329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Clara Kwan
- Department of Medicine, Maimonides Medical Center, Brooklyn, New York
| | - Yu Shia Lin
- Department of Medicine, Maimonides Medical Center, Brooklyn, New York
| | - Peter Homel
- Department of Medicine, Department of Research, Maimonides Medical Center, Brooklyn, New York.,Albert Einstein College of Medicine, Yeshiva University, Bronx, New York
| | - Mary Rojas
- Department of Research Administration, Maimonides Medical Center, Brooklyn, New York
| | - Vijay Shetty
- Department of Medicine, Maimonides Medical Center, Brooklyn, New York.,Albert Einstein College of Medicine, Yeshiva University, Bronx, New York
| | - Edgar Lichstein
- Department of Medicine, Maimonides Medical Center, Brooklyn, New York.,Albert Einstein College of Medicine, Yeshiva University, Bronx, New York
| |
Collapse
|
8
|
Thakar S, Koshkelashvili N, Bucay MJ, Lichstein E, Saqid A, Pressman GS, Figueredo VM. Electrocardiographic changes in patients ≥100years of age. Int J Cardiol 2016; 210:156-7. [DOI: 10.1016/j.ijcard.2016.02.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Accepted: 02/20/2016] [Indexed: 10/22/2022]
|
9
|
Sharma A, Lavie C, Vallakati A, Garg A, Goel S, Lichstein E, Mukherjee D, Lazar J. EFFECT OF CARDIAC RESYNCHRONIZATION THERAPY ON RIGHT VENTRICULAR FUNCTION. J Am Coll Cardiol 2016. [DOI: 10.1016/s0735-1097(16)31489-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Sharma A, Bax JJ, Vallakati A, Goel S, Lavie CJ, Garg A, Mukherjee D, Lichstein E, Lazar JM. Effect of cardiac resynchronization therapy on right ventricular function. Int J Cardiol 2016; 209:34-6. [DOI: 10.1016/j.ijcard.2016.02.034] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Accepted: 02/02/2016] [Indexed: 11/26/2022]
|
11
|
Benhorin J, Bodenheimer M, Brown M, Case R, Dwyer EM, Eberly S, Francis C, Gillespie JA, Goldstein RE, Greenberg H, Haigney M, Krone RJ, Klein H, Lichstein E, Locati E, Marcus FI, Moss AJ, Oakes D, Ryan DH, Bloch Thomsen PE, Zareba W. Improving clinical practice guidelines for practicing cardiologists. Am J Cardiol 2015; 115:1773-6. [PMID: 25918027 DOI: 10.1016/j.amjcard.2015.03.026] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Revised: 03/10/2015] [Accepted: 03/10/2015] [Indexed: 11/15/2022]
Abstract
Cardiac-related clinical practice guidelines have become an integral part of the practice of cardiology. Unfortunately, these guidelines are often long, complex, and difficult for practicing cardiologists to use. Guidelines should be condensed and their format upgraded, so that the key messages are easier to comprehend and can be applied more readily by those involved in patient care. After presenting the historical background and describing the guideline structure, we make several recommendations to make clinical practice guidelines more user-friendly for clinical cardiologists. Our most important recommendations are that the clinical cardiology guidelines should focus exclusively on (1) class I recommendations with established benefits that are supported by randomized clinical trials and (2) class III recommendations for diagnostic or therapeutic approaches in which quality studies show no benefit or possible harm. Class II recommendations are not evidence based but reflect expert opinions related to published clinical studies, with potential for personal bias by members of the guideline committee. Class II recommendations should be published separately as "Expert Consensus Statements" or "Task Force Committee Opinions," so that both majority and minority expert opinions can be presented in a less dogmatic form than the way these recommendations currently appear in clinical practice guidelines.
Collapse
Affiliation(s)
| | | | | | - Robert Case
- Emeritus, St. Luke's-Roosevelt Hospital Center
| | | | | | | | | | | | - Henry Greenberg
- Mailman School of Public Health, Columbia University, New York City, New York
| | - Mark Haigney
- Uniformed Services University of the Health Sciences
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Sharma A, Thakar S, Lavie CJ, Garg J, Krishnamoorthy P, Sochor O, Arbab-Zadeh A, Lichstein E. Cardiovascular adverse events associated with smoking-cessation pharmacotherapies. Curr Cardiol Rep 2014; 17:554. [PMID: 25410148 DOI: 10.1007/s11886-014-0554-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Smoking continues to be the leading cause of preventable deaths in the USA, accounting for one in every five deaths every year, and cardiovascular (CV) disease remains the leading cause of those deaths. Hence, there is increasing awareness to quit smoking among the public and counseling plays an important role in smoking cessation. There are different pharmacological methods to help quit smoking that includes nicotine replacement products available over the counter, including patch, gum, and lozenges, to prescription medications, such as bupropion and varenicline. There have been reports of both nonserious and serious adverse CV events associated with the use of these different pharmacological methods, especially varenicline, which has been gaining media attention recently. Therefore, we systematically reviewed the various pharmacotherapies used in smoking cessation and analyzed the evidence behind these CV events reported with these therapeutic agents.
Collapse
Affiliation(s)
- Abhishek Sharma
- Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA,
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Sharma A, Garg A, Borer JS, Krishnamoorthy P, Garg J, Lavie CJ, Arbab-Zadeh A, Mukherjee D, Ahmad H, Lichstein E. Role of oral factor Xa inhibitors after acute coronary syndrome. Cardiology 2014; 129:224-32. [PMID: 25402219 DOI: 10.1159/000368747] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 09/26/2014] [Indexed: 11/19/2022]
Abstract
Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.
Collapse
Affiliation(s)
- Abhishek Sharma
- Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, New York, N.Y., USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Chatterjee S, Udell JA, Sardar P, Lichstein E, Ryan JJ. Comparable Benefit of β-Blocker Therapy in Heart Failure Across Regions of the World: Meta-analysis of Randomized Clinical Trials. Can J Cardiol 2014; 30:898-903. [DOI: 10.1016/j.cjca.2014.03.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Revised: 03/12/2014] [Accepted: 03/12/2014] [Indexed: 10/25/2022] Open
|
15
|
Sharma A, Vallakati A, Einstein AJ, Lavie CJ, Arbab-Zadeh A, Lopez-Jimenez F, Mukherjee D, Lichstein E. Relationship of body mass index with total mortality, cardiovascular mortality, and myocardial infarction after coronary revascularization: evidence from a meta-analysis. Mayo Clin Proc 2014; 89:1080-100. [PMID: 25039038 DOI: 10.1016/j.mayocp.2014.04.020] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2013] [Revised: 03/18/2014] [Accepted: 04/17/2014] [Indexed: 12/22/2022]
Abstract
OBJECTIVE To investigate the relationship of body mass index (BMI) with total mortality, cardiovascular (CV) mortality, and myocardial infarction (MI) after coronary revascularization procedures (coronary artery bypass grafting [CABG] and percutaneous coronary intervention [PCI]). PATIENTS AND METHODS Systematic search of studies was conducted using PubMed, CINAHL, Cochran CENTRAL, Scopus, and the Web of Science databases. We identified studies reporting the rate of MI, CV mortality, and total mortality among coronary artery disease patients' postcoronary revascularization procedures in various BMI categories: less than 20 (underweight), 20-24.9 (normal reference), 25-29.9 (overweight), 30-34.9 (obese), and 35 or more (severely obese). Event rates were compared using a random effects model assuming interstudy heterogeneity. RESULTS A total of 36 studies (12 CABG; 26 PCI) were selected for final analyses. The risk of total mortality (relative risk [RR], 2.59; 95% CI, 2.09-3.21), CV mortality (RR, 2.67; 95% CI, 1.63-4.39), and MI (RR, 1.79; 95% CI, 1.28-2.50) was highest among patients with low BMI at the end of a mean follow-up period of 1.7 years. The risk of CV mortality was lowest among overweight patients (RR, 0.81; 95% CI, 0.68-0.95). Increasing degree of adiposity as assessed by BMI had a neutral effect on the risk of MI for overweight (RR, 0.92; 95% CI, 0.84-1.01), obese (RR, 0.99; 95% CI, 0.85-1.15), and severely obese (RR, 0.93; 95% CI, 0.78-1.11) patients. CONCLUSION After coronary artery disease revascularization procedures (PCI and CABG), the risk of total mortality, CV mortality, and MI was highest among underweight patients as defined by low BMI and CV mortality was lowest among overweight patients.
Collapse
Affiliation(s)
- Abhishek Sharma
- Department of Medicine, Maimonides Medical Center, Brooklyn, NY.
| | - Ajay Vallakati
- Division of Cardiology, University of Kansas Medical Center, Kansas City
| | - Andrew J Einstein
- Division of Cardiology, Department of Medicine, and Department of Radiology, Columbia University Medical Center, New York, NY
| | - Carl J Lavie
- Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, the University of Queensland School of Medicine, New Orleans, LA; Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge
| | - Armin Arbab-Zadeh
- Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD
| | | | | | - Edgar Lichstein
- Department of Medicine, Maimonides Medical Center, Brooklyn, NY
| |
Collapse
|
16
|
Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, Homel P, Borer JS, Lichstein E. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol 2014; 113:1815-21. [PMID: 24837258 DOI: 10.1016/j.amjcard.2014.03.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Revised: 03/06/2014] [Accepted: 03/06/2014] [Indexed: 12/17/2022]
Abstract
Clinical studies suggest an association between bisphosphonate use and new-onset atrial fibrillation (AF). Intravenous bisphosphonates more potently increase the release of inflammatory cytokines than do oral bisphosphonates; thus, the risk of developing AF may be greater with intravenous preparations. We have evaluated incidence of new-onset AF with use of oral and intravenous bisphosphonates through a systematic review and meta-analysis of the literature. We searched PubMed, CINAHL, Cochrane Central Register of Controlled Trials, Scopus, and EMBASE databases for observational studies and randomized controlled trials (RCTs) published from 1966 to April 2013 that reported the number of patients developing AF with use of oral or intravenous bisphosphonates. The random-effects Mantel-Haenszel test was used to evaluate the relative risk of AF with use of oral and intravenous bisphosphonates. Nine studies (5 RCTs and 4 observational studies) were included in the final analysis. Pooled data from RCTs and observational studies (n = 135,347) showed a statistically significantly increased risk of new-onset AF with both intravenous (relative risk 1.40, 95% confidence interval 1.32 to 1.49) and oral (relative risk 1.22, 95% confidence interval 1.14 to 1.31) bisphosphonates. The z statistic, which assesses the difference between the 2 risk ratios, indicated higher risk of AF with intravenous bisphosphonates versus oral bisphosphonates (p = 0.03). In conclusion, pooled data from RCTs and observational studies suggest that risk of AF is increased by use of oral or intravenous bisphosphonates but further suggest that risk is relatively greater with intravenous preparations.
Collapse
|
17
|
Sharma A, Vallakati A, Einstein A, Lavie C, Arbab-Zadeh A, Lopez-Jimenez F, Mukherjee D, Lichstein E. RELATIONSHIP OF BODY MASS INDEX WITH TOTAL MORTALITY, CARDIOVASCULAR MORTALITY AND MYOCARDIAL INFARCTION AFTER CORONARY REVASCULARIZATION: EVIDENCE FROM A META-ANALYSIS. J Am Coll Cardiol 2014. [DOI: 10.1016/s0735-1097(14)61355-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, Lichstein E, McNitt S, Moss AJ, Pfeffer MA, Solomon SD. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail 2014; 16:560-5. [PMID: 24578164 DOI: 10.1002/ejhf.71] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2013] [Revised: 01/07/2014] [Accepted: 01/10/2014] [Indexed: 11/12/2022] Open
Abstract
AIMS Hospitalization for worsening heart failure (HF) is known to increase mortality and morbidity risk and has been frequently used as an endpoint in randomized clinical trials. Whether outpatient management of HF exacerbation carries similar prognostic and therapeutic information is less well known, but could be important for the design of trials that use HF hospitalization as an endpoint. METHODS AND RESULTS MADIT-CRT randomized patients with mild HF symptoms to resynchronization therapy vs. control with an average follow-up of 3.3 years and a total of 191 deaths. HF events were centrally adjudicated for receiving i.v. decongestive therapy in an outpatient setting, or an augmented HF regimen during a hospital stay. Patients were compared according to whether their first HF was an out- or inpatient event. The first primary event was non-fatal outpatient HF, non-fatal inpatient HF, and death in 52, 331, and 78 patients, respectively. Patients with inpatient HF tended to be older and more likely to have HF of ischaemic aetiology than subjects who developed outpatient HF events. The risk of death following either type of non-fatal HF events was extremely high [hazard ratio (HR) 12.4, 95% confidence interval (CI) 9.1-16.9 for inpatient HF; HR 10.7, 95% CI 6.1-18.7 for outpatient HF] compared with subjects without non-fatal HF events. Allocation to CRT-D was associated with significant reduction in both types of HF. CONCLUSION Outpatient management of worsening HF portends a high risk of death, similar to inpatient HF events, and may be equally sensitive to the effects of therapy. These findings suggest that outpatient HF events should be considered in publicly reported outcomes measures and future HF clinical trials. TRIAL REGISTRATION NCT01294449.
Collapse
Affiliation(s)
- Hicham Skali
- Harvard Medical School, Brigham and Women's Hospital, Cardiovascular Division, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Mukherjee D, Lichstein E. Meta-analysis of global left ventricular function comparing multidetector computed tomography with cardiac magnetic resonance imaging. Am J Cardiol 2014; 113:731-8. [PMID: 24355312 DOI: 10.1016/j.amjcard.2013.11.016] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2013] [Revised: 11/06/2013] [Accepted: 11/06/2013] [Indexed: 11/17/2022]
Abstract
We compare the diagnostic accuracy of multidetector row computed tomography (MDCT) to cardiac magnetic resonance imaging (CMR) for evaluating global left ventricular function. We systematically searched PubMed, CINAHL, Cochrane CENTRAL, Scopus, and the Web of Science databases for studies published between 1966 to January 2013 that compared left ventricle (LV) volumes, ejection fraction (EF) and LV mass measured by MDCT and CMR. We performed meta-analyses and used random-effects model with inverse variance weighting test to determine the overall bias and limits of agreement of LV end-diastolic volume, end-systolic volume, stroke volume, and EF measured by MDCT and CMR. Furthermore, subgroup analyses were performed to compare 16-slice and 64-slice MDCT with CMR. Two study authors independently reviewed the 90 articles originally identified and selected 27 studies (n = 831) for analysis. Excellent correlation and a linear relation were seen between MDCT and CMR for LV end-diastolic volume (r = 0.93; p <0.001), LV end-systolic volume (r = 0.95; p <0.001), LV stroke volume (r = 0.85; p <0.001), LV ejection fraction (r = 0.93; p <0.001), and LV mass (r = 0.86; p <0.001). Subgroup analyses showed strong positive correlations for both 16- and 64-slice MDCT. In conclusion, although not the first-line test for LV function assessment in most patients, when appropriate, retrospectively gated MDCT provides an accurate and valid assessment of LV function compared with CMR.
Collapse
Affiliation(s)
- Abhishek Sharma
- Department of Medicine, Maimonides Medical Center, Brooklyn, New York.
| | - Andrew J Einstein
- Division of Cardiology, Columbia University Medical Center, New York, New York
| | - Ajay Vallakati
- Division of Cardiology, University of Kansas Medical Center, Kansas City, Kansas
| | - Armin Arbab-Zadeh
- Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | | | - Edgar Lichstein
- Department of Medicine, Maimonides Medical Center, Brooklyn, New York
| |
Collapse
|
20
|
Chatterjee S, Sharma A, Lichstein E, Mukherjee D. Intensive glucose control in diabetics with an acute myocardial infarction does not improve mortality and increases risk of hypoglycemia-a meta-regression analysis. Curr Vasc Pharmacol 2013. [PMID: 22724474 DOI: 10.2174/1570161111309010100] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVES Some early trials comparing intensive glucose control in type 2 diabetics with an acute myocardial infarction (MI) reported a decrease in mortality over a short period of follow up leading to a presumption of improved survival with intensive glucose control. Later data refuted this hypothesis. The 2009 ACC/AHA focused update on ST elevation MI gave a weak recommendation for the use of an insulin based regimen to achieve and maintain blood glucose less than 180 mg/dL. We decided to assess the validity of this recommendation. METHODS The authors searched the Pub- Med, Cochrane CENTRAL and EMBASE databases for randomized controlled trials from 1965 through 2011.Trials included were direct head-to-head comparisons of an intensive blood glucose control strategy using pharmacological means (insulin in most cases) with a less intensive regimen. The primary outcome assessed was the risk of all -cause mortality in the two groups at the end of follow up. Also assessed was the rate of hypoglycemia. The methodological quality of the studies was assessed. Event rates were compared using a forest plot of relative risk (RR; 95% confidence interval [CI]) using a random effects model (Mantel-Haenszel) assuming inter-study heterogeneity. Statistical analysis was done with Review Manager V5.1 and SYSTAT. Meta-regression was done with duration of therapy as covariate. RESULTS Three studies (total N = 2113) met the inclusion exclusion criteria. Mortality was not different between the groups (RR 0.94, 95% CI of 0.66-1.34; p=0.73.). Rate of hypoglycemia was significantly higher in the intensive glucose control group (RR 13.40, 95% CI 3.69-48.61; p < 0.01), with a 12% absolute risk increase and a number needed to harm (NNH) of 9 (95% CI 6.8- 9.8)-even without achieving target glycemic control. Neither did intensive control improve CHF, arrhythmias and reinfarction rates. Meta regression revealed that mortality with intensive glycemic control was worse with increased duration of therapy (p=0.001, for trend). CONCLUSIONS This systematic review suggests limited benefit of intensive glycemic control in type 2 diabetics with an MI, with a significant risk of serious hypoglycemia.
Collapse
Affiliation(s)
- Saurav Chatterjee
- Maimonides Medical Center, 864 49th Street Apt C11, Brooklyn, NY 11220, USA.
| | | | | | | |
Collapse
|
21
|
Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, Aikat S, Mukherjee D. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One 2013; 8:e77694. [PMID: 24204920 PMCID: PMC3808395 DOI: 10.1371/journal.pone.0077694] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Accepted: 09/03/2013] [Indexed: 11/23/2022] Open
Abstract
Purpose Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all risk stratification schemes. A systematic review and meta-analysis was performed to compare the efficacy and safety of New Oral Anticoagulants (NOACs) to warfarin in patients with AF and previous stroke or transient ischemic attack (TIA). Methods Three randomized controlled trials (RCTs), including total 14527 patients, comparing NOACs (apixaban, dabigatran and rivaroxaban) with warfarin were included in the analysis. Primary efficacy endpoint was ischemic stroke, and primary safety endpoint was intracranial bleeding. Random-effects models were used to pool efficacy and safety data across RCTs. RevMan and Stata software were used for direct and indirect comparisons, respectively. Results In patients with AF and previous stroke or TIA, effects of NOACs were not statistically different from that of warfarin, in reduction of stroke (Odds Ratio [OR] 0.86, 95% confidence interval [CI] 0.73- 1.01), disabling and fatal stroke (OR 0.85, 95% CI 0.71-1.04), and all-cause mortality (OR 0.90, 95% CI 0.79 -1.02). Randomization to NOACs was associated with a significantly lower risk of intracranial bleeding (OR 0.42, 95% CI 0.25-0.70). There were no major differences in efficacy between apixaban, dabigatran (110 mg BID and 150 mg BID) and rivaroxaban. Major bleeding was significantly lower with apixaban and dabigatran (110 mg BID) compared with dabigatran (150 mg BID) and rivaroxaban. Conclusion NOACs may not be more effective than warfarin in the secondary prevention of ischemic stroke in patients with a prior history of cerebrovascular ischemia, but have a lower risk of intracranial bleeding.
Collapse
Affiliation(s)
- Partha Sardar
- Department of Medicine, New York Medical College, Metropolitan Hospital Center, New York, New York, United States of America
- * E-mail:
| | - Saurav Chatterjee
- Brown University and the Providence VAMC, Providence, Rhode Island, United States of America
| | - Wen-Chih Wu
- Brown University and the Providence VAMC, Providence, Rhode Island, United States of America
| | - Edgar Lichstein
- Maimonides Medical Center, Brooklyn, New York, United States of America
| | - Joydeep Ghosh
- Maimonides Medical Center, Brooklyn, New York, United States of America
| | - Shamik Aikat
- Division of Cardiology, Gill Heart Institute, University of Kentucky, Lexington, Kentucky, United States of America
| | - Debabrata Mukherjee
- Texas Tech University Health Sciences Center, El Paso, Texas, United States of America
| |
Collapse
|
22
|
Sharma A, Chatterjee S, Shetty VS, Lichstein E. Sensitivity and specificity of commonly used EKG criterion to assess left ventricular hypertrophy in centenarians. Int J Cardiol 2013; 168:3102-3. [DOI: 10.1016/j.ijcard.2013.04.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2013] [Accepted: 04/06/2013] [Indexed: 10/26/2022]
|
23
|
Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J, Aikat S. Risk of Serious Atrial Fibrillation and Stroke With Use of Bisphosphonates. Chest 2013; 144:1311-1322. [DOI: 10.1378/chest.13-0675] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
24
|
Sharma A, Chatterjee S, Thakar S, Lichstein E. Apical ballooning in patients with coronary artery disease versus takotsubo cardiomyopathy—A case control study. Int J Cardiol 2013; 166:738-9. [DOI: 10.1016/j.ijcard.2012.09.182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Accepted: 09/25/2012] [Indexed: 11/28/2022]
|
25
|
Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E. RISK OF SERIOUS ATRIAL FIBRILLATION AND STROKE WITH USE OF BISPHOSPHONATES: EVIDENCE FROM A META-ANALYSIS. J Am Coll Cardiol 2013. [DOI: 10.1016/s0735-1097(13)61579-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Sharma A, Chatterjee S, Wu WC, Lichstein E. RISK OF CARDIAC MORTALITY AND MYOCARDIAL INFARCTIONS IN BMI<20 KG/M2: CAN RATES OF MYOCARDIAL INFARCTIONS EXPLAIN THE HIGHER CARDIAC MORTALITY? J Am Coll Cardiol 2013. [DOI: 10.1016/s0735-1097(13)61533-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med 2013; 173:132-9. [PMID: 23266500 DOI: 10.1001/2013.jamainternmed.1001] [Citation(s) in RCA: 139] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND The benefit of blood transfusion in patients with myocardial infarction is controversial, and a possibility of harm exists. METHODS A systematic search of studies published between January 1, 1966, and March 31, 2012, was conducted using MEDLINE, EMBASE, CINAHL, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials databases. English-language studies comparing blood transfusion with no blood transfusion or a liberal vs restricted blood transfusion strategy were identified. Two study authors independently reviewed 729 originally identified titles and abstracts and selected 10 for analysis. Study title, follow-up period, blood transfusion strategy, and mortality outcomes were extracted manually from all selected studies, and the quality of each study was assessed using the strengthening Meta-analysis of Observational Studies in Epidemiology checklist. RESULTS Studies of blood transfusion strategy in anemia associated with myocardial infarction were abstracted, as well as all-cause mortality rates at the longest available follow-up periods for the individual studies. Pooled effect estimates were calculated with random-effects models. Analyses of blood transfusion in myocardial infarction revealed increased all-cause mortality associated with a strategy of blood transfusion vs no blood transfusion during myocardial infarction (18.2% vs 10.2%) (risk ratio, 2.91; 95% CI, 2.46-3.44; P < .001), with a weighted absolute risk increase of 12% and a number needed to harm of 8 (95% CI, 6-17). Multivariate meta-regression revealed that blood transfusion was associated with a higher risk for mortality independent of baseline hemoglobin level, nadir hemoglobin level, and change in hemoglobin level during the hospital stay. Blood transfusion was also significantly associated with a higher risk for subsequent myocardial infarction (risk ratio, 2.04; 95% CI, 1.06-3.93; P = .03). CONCLUSIONS Blood transfusion or a liberal blood transfusion strategy compared with no blood transfusion or a restricted blood transfusion strategy is associated with higher all-cause mortality rates. A practice of routine or liberal blood transfusion in myocardial infarction should not be encouraged but requires investigation in a large trial with low risk for bias.
Collapse
Affiliation(s)
- Saurav Chatterjee
- Division of Cardiology, Department of Medicine, Brown University, and Providence Veterans Affairs Medical Center, Providence, RI 02904, USA.
| | | | | | | | | |
Collapse
|
28
|
Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013; 346:f55. [PMID: 23325883 PMCID: PMC3546627 DOI: 10.1136/bmj.f55] [Citation(s) in RCA: 178] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE To clarify whether any particular β blocker is superior in patients with heart failure and reduced ejection fraction or whether the benefits of these agents are mainly due to a class effect. DESIGN Systematic review and network meta-analysis of efficacy of different β blockers in heart failure. DATA SOURCES CINAHL(1982-2011), Cochrane Collaboration Central Register of Controlled Trials (-2011), Embase (1980-2011), Medline/PubMed (1966-2011), and Web of Science (1965-2011). STUDY SELECTION Randomized trials comparing β blockers with other β blockers or other treatments. DATA EXTRACTION The primary endpoint was all cause death at the longest available follow-up, assessed with odds ratios and Bayesian random effect 95% credible intervals, with independent extraction by observers. RESULTS 21 trials were included, focusing on atenolol, bisoprolol, bucindolol, carvedilol, metoprolol, and nebivolol. As expected, in the overall analysis, β blockers provided credible mortality benefits in comparison with placebo or standard treatment after a median of 12 months (odds ratio 0.69, 0.56 to 0.80). However, no obvious differences were found when comparing the different β blockers head to head for the risk of death, sudden cardiac death, death due to pump failure, or drug discontinuation. Accordingly, improvements in left ventricular ejection fraction were also similar irrespective of the individual study drug. CONCLUSION The benefits of β blockers in patients with heart failure with reduced ejection fraction seem to be mainly due to a class effect, as no statistical evidence from current trials supports the superiority of any single agent over the others.
Collapse
Affiliation(s)
- Saurav Chatterjee
- Division of Internal Medicine, Maimonides Medical Center, New York, NY, USA.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Chatterjee S, Sharma A, Lichstein E, Mukherjee D. Intensive Glucose Control in Diabetics with an Acute Myocardial Infarction Does not Improve Mortality and Increases Risk of Hypoglycemia-A Meta-Regression Analysis. Curr Vasc Pharmacol 2013. [DOI: 10.2174/157016113804547548] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
30
|
Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost 2012; 10:2053-60. [PMID: 22863355 DOI: 10.1111/j.1538-7836.2012.04874.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
BACKGROUND Duration of thromboprophylaxis beyond hospital discharge for medically ill patients has been controversial. Therefore an evaluation was made of the evidence currently available. METHODS A search was made of the Pub Med, CENTRAL and EMBASE databases for randomized controlled trials from 1966 through to 2011. Interventions included thromboprophylaxis administered over an extended period in patients hospitalized for acute medical illness with decreased level of mobility. No differentiation was made for the medication used for individual studies. The comparator included standard medical therapy and/or placebo. The efficacy outcomes assessed were a composite of asymptomatic and symptomatic deep vein thromboses (DVT), pulmonary emboli (PE) and venous thromboembolism (VTE)-related deaths in the intervention group vs. the comparator group, as well as the safety outcomes evaluated with rates of bleeding events at the end of at least 30 days of follow-up. The methodological quality of the studies was assessed, as was publication bias. Event rates were compared using a forest plot of relative risk (RR; 95% confidence interval (CI)) using a random effects model (Mantel-Haenszel) between the active thromboprophylaxis and controls. Statistical analysis was carried out with Review Manager V5.1. RESULTS Three recent studies were included. Extended duration thromboprophylaxis reduced the combined composite event rate, RR 0.75 (0.64, 0.88). However, individual clinical endpoints were not significantly improved with extended prophylaxis: asymptomatic proximal DVT, RR 0.85 (0.68, 1.05); symptomatic DVT, RR 0.44 (0.19, 1.00); symptomatic non-fatal PE, RR 0.80 (0.43, 1.48); VTE-related death, RR 0.64 (0.38, 1.10). However, bleeding events were far more prevalent with extended thromboprophylaxis with major bleeds, RR 2.68 (1.78, 4.05), with a number needed to harm of 194. CONCLUSION Currently available evidence does not indicate that routine administration of post-discharge prophylaxis will be beneficial to the patients admitted for medical illness.
Collapse
Affiliation(s)
- A Sharma
- Department of Medicine, Maimonides Medical Center, Brooklyn, NY, USA.
| | | | | | | |
Collapse
|
31
|
Thakar S, Shetty V, Sadiq A, Lichstein E, Hollander G, Shani J. Abstract 100: Electrocardiographic Changes in Patients ≥ 100 Years Of Age. Hypertension 2012. [DOI: 10.1161/hyp.60.suppl_1.a100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
Centenarian population in the United States is increasing, and cardiovascular disease is the most common cause of death in this group of patients. We report electrocardiographic changes in a group of 124 centenarians.
METHODS:
We included ECGs of 124 patients aged 100 to 112 years (mean age 102 years), who were seen either on office visits or on recent admission to the hospital. ECGs were analyzed by 2 different investigators.
Results:
Women were at least 2 times men in number (31% vs 69%, 39 vs 85 of 124); thus women outlived men in the centenarian group. 58% (72 of 124) patients had normal sinus rhythm and only 7 of 124 patients (6%, all women) had normal ECGs. The most common electrocardiographic abnormalities were: left-axis deviation (29%, 36 of 124), atrial fibrillation (AF) (27%, 34 of 124), right bundle branch block (15%, 18 of 124), left anterior fascicular block (14%, 17 of 124), left ventricular hypertrophy (14%, 17 of 124), first-degree atrioventricular (AV) block (13%, 16 of 124), nonspecific ST-T changes (13%, 16 of 124), premature atrial complexes (13%, 16 of 124), premature ventricular complexes (10%, 13 of 124) and pacemaker rhythm (10%, 13 of 124). Almost all Q waves were suggestive of old inferior wall infarcts and were present in 8% (10 of 124) of patients. Only 3 centenarians had QTc prolongation.
Conclusion:
Fewer men live long enough to reach 100 years of age, consistent with higher incidence of ischemic heart disease in men. Centenarians had higher incidence of AF indicative of increased incidence of AF with age. Increased incidence of left-axis deviation, left anterior fascicular block and left ventricular hypertrophy in centenarians can be attributed to age related cardiac hypertrophy and prevalence of hypertension. Also higher prevalence of conduction disturbances including AV block and bundle branch block indicates that a degenerative conduction system disorder may progress with advancing age. The finding of pacemaker rhythm in a few subjects confirms that pacemaker implantation may allow some patients to reach extreme longevity. Overall centenarians represent a model of successful aging and have satisfactory electrocardiographic framework that reflects a good cardiac function, contributing to attainment of extreme longevity.
Collapse
|
32
|
Chatterjee S, Ghosh J, Lichstein E, Aikat S, Mukherjee D. Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012; 110:607-13. [PMID: 22608952 DOI: 10.1016/j.amjcard.2012.04.034] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Revised: 04/03/2012] [Accepted: 04/03/2012] [Indexed: 11/24/2022]
Abstract
Dronedarone is a benzofuran derivative approved by the Food and Drug Administration to decrease the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) and associated cardiovascular risk factors who are in sinus rhythm or will undergo cardioversion. There has been recent evidence to suggest that dronedarone may not have a favorable safety profile. We decided to evaluate all available evidence on the cardiovascular safety of this drug. A systematic search was made of the PubMed, CENTRAL, and EMBASE databases for randomized controlled trials from 1966 through 2011 comparing dronedarone to comparators in AF/heart failure. Intervention was dronedarone for AF for some studies and heart failure for others. Comparators included standard medical therapy and/or placebo and amiodarone for 1 study. Outcomes assessed were all-cause mortality, cardiovascular mortality, ventricular arrhythmias, embolic events, acute coronary syndrome, heart failure exacerbations, and hospitalization rates in the intervention versus comparator group at the end of ≥ 3 months of follow up with abstraction of data by 1 author. Seven randomized controlled trials were included in our analysis. Dronedarone use was associated with a trend toward worse all-cause and cardiovascular mortalities and increased heart failure exacerbations. It also showed numerically higher event rates for all other outcome events except acute coronary syndrome. Our pooled analysis showed increased all-cause and cardiovascular mortalities and increased heart failure exacerbations with use of dronedarone across a wide spectrum of populations. In conclusion, we recommend exercising caution using dronedarone, especially in patients with cardiovascular risk factors.
Collapse
|
33
|
Thakar S, Janga KC, Tolchinsky T, Greenberg S, Sharma K, Sadiq A, Lichstein E, Shani J. Superior vena cava and right atrium wall infective endocarditis in patients receiving hemodialysis. Heart Lung 2012; 41:301-7. [DOI: 10.1016/j.hrtlng.2011.06.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2011] [Revised: 06/25/2011] [Accepted: 06/30/2011] [Indexed: 10/17/2022]
|
34
|
Chatteriee S, sardar P, Mukherjee D, Lichstein E, Aikat S. OPTIMAL TIMING AND ROUTE OF AMIODARONE FOR PREVENTION OF POST OPERATIVE ATRIAL FIBRILLATION AFTER CARDIAC SURGERY -A NETWORK REGRESSION META-ANALYSIS. J Am Coll Cardiol 2012. [DOI: 10.1016/s0735-1097(12)60687-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Chatterjee S, Moeller C, Shah N, Bolorunduro O, Moskovits N, Lichstein E, Mukherjee D. AN INDIRECT POOLED COMPARISON OF CLINICAL ENDPOINTS WITH EPLERENONE AND OTHER ALDOSTERONE ANTAGONISTS IN HEART FAILURE-A SYSTEMATIC REVIEW. J Am Coll Cardiol 2012. [DOI: 10.1016/s0735-1097(12)62147-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, Cannom D, Daubert JP, Eldar M, Gold MR, Goldberger JJ, Goldenberg I, Lichstein E, Pitschner H, Rashtian M, Solomon S, Viskin S, Wang P, Moss AJ. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011; 123:1061-72. [DOI: 10.1161/circulationaha.110.960898] [Citation(s) in RCA: 610] [Impact Index Per Article: 46.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
This study aimed to determine whether QRS morphology identifies patients who benefit from cardiac resynchronization therapy with a defibrillator (CRT-D) and whether it influences the risk of primary and secondary end points in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) trial.
Methods and Results—
Baseline 12-lead ECGs were evaluated with regard to QRS morphology. Heart failure event or death was the primary end point of the trial. Death, heart failure event, ventricular tachycardia, and ventricular fibrillation were secondary end points. Among 1817 patients with available sinus rhythm ECGs at baseline, there were 1281 (70%) with left bundle-branch block (LBBB), 228 (13%) with right bundle-branch block, and 308 (17%) with nonspecific intraventricular conduction disturbances. The latter 2 groups were defined as non-LBBB groups. Hazard ratios for the primary end point for comparisons of CRT-D patients versus patients who only received an implantable cardioverter defibrillator (ICD) were significantly (
P
<0.001) lower in LBBB patients (0.47;
P
<0.001) than in non-LBBB patients (1.24;
P
=0.257). The risk of ventricular tachycardia, ventricular fibrillation, or death was decreased significantly in CRT-D patients with LBBB but not in non-LBBB patients. Echocardiographic parameters showed significantly (
P
<0.001) greater reduction in left ventricular volumes and increase in ejection fraction with CRT-D in LBBB than in non-LBBB patients.
Conclusions—
Heart failure patients with New York Heart Association class I or II and ejection fraction ≤30% and LBBB derive substantial clinical benefit from CRT-D: a reduction in heart failure progression and a reduction in the risk of ventricular tachyarrhythmias. No clinical benefit was observed in patients with a non-LBBB QRS pattern (right bundle-branch block or intraventricular conduction disturbances).
Clinical Trial Registration—
URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT00180271.
Collapse
Affiliation(s)
- Wojciech Zareba
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Helmut Klein
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Iwona Cygankiewicz
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - W. Jackson Hall
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Scott McNitt
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Mary Brown
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - David Cannom
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - James P. Daubert
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Michael Eldar
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Michael R. Gold
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Jeffrey J. Goldberger
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Ilan Goldenberg
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Edgar Lichstein
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Heinz Pitschner
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Mayer Rashtian
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Scott Solomon
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Sami Viskin
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Paul Wang
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| | - Arthur J. Moss
- From the Cardiology Division (W.Z., H.K., I.C., S.M., M.B., I.G., A.J.M.) and Department of Biostatistics and Computational Biology (W.J.H.), University of Rochester, Rochester, NY; The Hospital of the Good Samaritan (D.C.), Los Angeles, CA; Cardiology Division (J.P.D.), Duke University, Durham, NC; Cardiology Division (M.E.), Chaim Sheba Medical Center, Tel Hashomer, Israel; Cardiology Division (M.R.G.), Medical University of South Carolina, Charleston, SC; Cardiology Division (J.J.G.),
| |
Collapse
|
37
|
Gadi VS, Nerella N, Thekkoott D, Malik B, Shani J, Lichstein E. A LOW LEVEL OF SOLUBLE CD40 LIGAND IN FIRST ENCOUNTER SAMPLES EXCLUDES PATIENTS WITH HIGH-RISK ANGIOGRAPHIC FEATURES BETTER THAN THAT OF TROPONIN I. Chest 2008. [DOI: 10.1378/chest.134.4_meetingabstracts.p85004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
38
|
Affiliation(s)
- Nitin Mahajan
- Department of Medicine, Maimonides Medical Center, Brooklyn, NY
| | | | | | | | | |
Collapse
|
39
|
Mahajan N, Mehta Y, Rose M, Shani J, Lichstein E. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol 2006; 111:442-9. [PMID: 16290105 DOI: 10.1016/j.ijcard.2005.08.029] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2005] [Revised: 08/06/2005] [Accepted: 08/29/2005] [Indexed: 11/26/2022]
Abstract
BACKGROUND Elevated troponin I in the absence of angiographically visible coronary lesions is seen in up to 10-15% of those undergoing angiography for suspected coronary artery disease. This study aims to elucidate the etiology of elevated cardiac troponin I in patients with normal coronary arteries on angiography. METHODS We identified 1551 (8.6%) patients with normal coronary arteries from our catheterization database of 17,950 patients from Jan 2000 to Jun 2004. Elevated troponin I levels were found in 217 (14%) of 1551 patients with normal coronary arteries. Of these 217 patients, 73 surgical patients were excluded, and the remaining 144 patients formed the study population. The study population was compared with age and gender matched patients with myocardial infarction and coronary artery disease (Group II). RESULTS The patients with elevated cardiac troponin I (cTnI) with normal coronary arteries had significantly lower prevalence of atherosclerotic risk factors and significantly higher left ventricular ejection fractions. The cTnI in patients with normal coronary arteries was elevated due to a number of causes including tachycardia, myocarditis, pericarditis, severe aortic stenosis, gastrointestinal bleeding, sepsis, left ventricular hypertrophy, severe congestive heart failure, cerebrovascular accident, electrical trauma, myocardial contusion, hypertensive emergency, myocardial bridging, pulmonary embolism, diabetic ketoacidosis, chronic obstructive pulmonary disease exacerbation and coronary spasm. CONCLUSIONS Cardiac troponin I could be elevated in a number of conditions, apart from acute myocardial infarction, and could reflect myonecrosis. Acute myocardial infarction is a clinical diagnosis as the laboratory is an aide to, not a replacement for, informed decision making.
Collapse
Affiliation(s)
- Nitin Mahajan
- Department of Medicine, Maimonides Medical Center, Brooklyn, NY 11219, USA.
| | | | | | | | | |
Collapse
|
40
|
Mahajan N, Hollander G, Thekkoott D, Temple B, Malik B, Abrol S, Yens D, Shani J, Lichstein E. Prediction of left main coronary artery obstruction by 12-lead electrocardiography: ST segment deviation in lead V6 greater than or equal to ST segment deviation in lead V1. Ann Noninvasive Electrocardiol 2006; 11:102-12. [PMID: 16630083 PMCID: PMC7313310 DOI: 10.1111/j.1542-474x.2006.00090.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Acute coronary syndrome (ACS) resulting from culprit lesion in left main coronary artery (LMCA) can cause rapid hemodynamic deterioration. It is important to identify these patients early to facilitate timely revascularization. ST segment elevation in aVR greater than or equal to V(1) (aVR-V(1)>or= 0) has been suggested as a sensitive predictor of LMCA disease. As a result of balanced forces, we hypothesized that ST deviation in V(6) greater than or equal to ST deviation in V(1) (V(6)-V(1)>or= 0) might be a good determinant of LMCA disease. METHODS We compared admission 12-lead ECGs of ACS resulting from culprit LMCA lesion (n = 75, group I) with ACS resulting from culprit left anterior descending lesion (n = 81, group II). Group I was selected over a period of 10 years. We compared V(6)-V(1)>or= 0 to aVR-V(1)>or= 0 in both groups. We also looked at ratios of ST deviations in V(6),V(1) (V(6)/V(1)>or= 1) and aVR,V(1) (aVR/V(1)>or= 1) in patients where ST segment in V(1) was not isoelectric (group I = 54 and group II = 55). RESULTS ST deviation in V(6) was significantly greater in group I as compared to group II (P < 0.001). The reliabilities of V(6)-V(1)>or= 0, V(6)/V(1)>or= 1, aVR-V(1)>or= 0, and aVR/V(1)>or= 1 in predicting LMCA disease were determined. CONCLUSION This is the largest series of ECG analysis on ACS resulting from culprit LMCA lesion. V(6)-V(1)>or= 0 and V(6)/V(1)>or= 1 were more sensitive in predicting LMCA as culprit vessel in comparison to previously reported greater ST segment elevation in aVR than V(1).
Collapse
Affiliation(s)
- Nitin Mahajan
- Department of Medicine, Maimonides Medical Center, Brooklyn, NY 11219, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Shetty V, Mahajan N, Thekkoott D, Shani J, Hollander G, Lichstein E, Greengart A, Kerstein J, Malik B. NUCLEAR STRESS TESTS IN ISOLATED AND SIGNIFICANT LEFT MAIN CORONARY ARTERY DISEASE: THERE IS NO UNIQUE PATTERN OF PERFUSION DEFICIT AND ABSENCE OF PERFUSION DEFICITS DOES NOT RULE OUT THE DIAGNOSIS. Chest 2005. [DOI: 10.1378/chest.128.4_meetingabstracts.278s-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
43
|
Mahajan N, Thekkoott D, Hollander G, Malik B, Abrol S, Shani J, Lichstein E. ISOLATED AND SIGNIFICANT LEFT MAIN CORONARY ARTERY DISEASE: DEMOGRAPHICS, HEMODYNAMICS AND ANGIOGRAPHIC FEATURES. Chest 2005. [DOI: 10.1378/chest.128.4_meetingabstracts.280s-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
44
|
Moss AJ, Ryan D, Oakes D, Goldstein RE, Greenberg H, Bodenheimer MM, Brown MW, Case RB, Dwyer EM, Eberly SW, Francis CW, Gillespie JA, Krone RJ, Lichstein E, MacCluer JW, Marcus FI, McCarthy J, Sparks CE, Zareba W. Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. Am J Cardiol 2005; 96:177-82. [PMID: 16018837 DOI: 10.1016/j.amjcard.2005.03.039] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2005] [Revised: 03/08/2005] [Accepted: 03/08/2005] [Indexed: 10/25/2022]
Abstract
The association of a group of prespecified atherosclerotic risk genotypes with recurrent coronary events (coronary-related death, nonfatal myocardial infarction, or unstable angina) was investigated in a cohort of 1,008 patients after infarction during an average follow-up of 28 months. We used a carrier-ship approach with time-dependent survivorship analysis to evaluate the average risk of each carried genotype. Contrary to expectation, the hazard ratio for recurrent coronary events per carried versus noncarried genotype was 0.89 (95% confidence interval 0.80 to 0.99, p = 0.03) after adjustment for relevant genetic, clinical, and environmental covariates. This hazard ratio, derived from the 7 prespecified genotypes, indicated an average 11% reduction in the risk of recurrent coronary events per carried versus noncarried genotype. At 1 year after hospital discharge, the cumulative probability of recurrent coronary events was 26% in those who carried < or =1, 20% for those with 2 to 4, and 13% for those with > or =5 of these genotypes (p = 0.02). This unexpected risk reversal is a likely consequence of changes in the mix of risk factors in pre- and postinfarction populations. In conclusion, this under appreciated, population-based, risk-reversal phenomenon may explain the inconsistent associations of genetic risk factors with outcome events in previous reports involving coronary populations with different risk attributes.
Collapse
Affiliation(s)
- Arthur J Moss
- Cardiology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Mohamed E, Lichstein E. 20-Year Follow-up of a Patient with Coronary Artery Spasm. South Med J 2004; 97:1010-2. [PMID: 15558933 DOI: 10.1097/01.smj.0000140854.65086.f9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The authors present a 20-year follow-up of a patient with well-documented coronary artery spasm, who initially presented with syncope. The patient had excellent response to calcium channel antagonists and long-acting nitrates.
Collapse
Affiliation(s)
- Elsayed Mohamed
- Department of Medicine, Maimonides Medical Center, 4802 10th Ave, New York, NY 11219, USA
| | | |
Collapse
|
46
|
Kerstein J, Soodan A, Qamar M, Majid M, Lichstein E, Hollander G, Shani J. Giving IV and Oral Amiodarone Perioperatively for the Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Surgery. Chest 2004; 126:716-24. [PMID: 15364747 DOI: 10.1378/chest.126.3.716] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
PURPOSES We studied the use of perioperative IV and oral administration of amiodarone for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass graft surgery (CABG). BACKGROUND In the United States, > 500,000 patients undergo CABG each year. Numerous studies to date have suggested that postoperative atrial fibrillation occurs in 30 to 50% of patients, leading to significant morbidity, including hypotension, heart failure, thromboembolic complications, prolonged hospital stay, and increased hospital costs. The objective of this study was to assess the use of IV amiodarone in combination with oral amiodarone to reduce the incidence of postoperative atrial fibrillation. METHOD From January 1999 to October 1999, 51 patients scheduled for CABG were randomly selected for participation in the amiodarone administration trial. IV amiodarone, 0.73 mg/min, was administered on call to the operating room for 48 h, followed by oral amiodarone, 400 mg q12h, for the next 3 days. The amiodarone group was case-control matched to the incidence of postoperative atrial fibrillation in 92 patients undergoing CABG using conventional medical therapy during the same period. The primary end point of this study was the incidence of postoperative atrial fibrillation, length of hospital stay, and hospital costs, compared to the control group undergoing CABG during the same time. RESULTS Atrial fibrillation occurred in 3 of 51 patients (5.88%) in the amiodarone group, compared to 24 of 92 patients (26.08%) in the control group. Length of hospital stay in the amiodarone group was less than in the control group (5.3 days vs 6.7 days), with a trend toward decrease in hospital costs. CONCLUSION The administration of IV amiodarone in conjunction with oral amiodarone for a total dose of 4,500 mg over 5 days appears to be a hemodynamically well-tolerated, safe, and effective treatment in decreasing the incidence of postoperative atrial fibrillation, shortening length of stay, and a trend toward lowering hospital costs, even in patients with significantly reduced left ventricular function (< 30%). A large multicenter study using IV and oral amiodarone should be pursued prior to deciding whether its use should become standard therapy in all patients undergoing CABG in order to decrease the incidence of postoperative atrial fibrillation.
Collapse
Affiliation(s)
- Joshua Kerstein
- Maimonides Medical Center, 953 49th St, Brooklyn, NY 11219, USA
| | | | | | | | | | | | | |
Collapse
|
47
|
Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ, Lichstein E. Relationship Between Intermittent Claudication, Inflammation, Thrombosis, and Recurrent Cardiac Events Among Survivors of Myocardial Infarction. ACTA ACUST UNITED AC 2004; 164:440-6. [PMID: 14980996 DOI: 10.1001/archinte.164.4.440] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
BACKGROUND Among coronary disease patients, concomitant peripheral arterial disease is a potent risk factor for future cardiac events and mortality. We sought to determine clinical and biochemical markers that might better elucidate the relationship between coronary and peripheral arterial disease. METHODS Two months after an index myocardial infarction, 1045 patients provided detailed medical histories and underwent blood testing for selected hemostatic, lipid, and inflammatory markers. Patients were then followed up prospectively for a mean of 26 months. RESULTS Compared with individuals without intermittent claudication (n = 966), those with claudication (n = 78) (information was unavailable for 1 individual) were significantly older and demonstrated an increased frequency of diabetes mellitus, tobacco use, prior cardiac and cerebrovascular events, and depressed left ventricular function. Individuals with claudication were less likely to receive beta-blocker therapy after the index infarction. Individuals with claudication had evidence of enhanced procoagulant and proinflammatory states manifested by relative elevations in plasma fibrinogen, D-dimer, C-reactive protein, and serum amyloid A concentrations. During follow-up, the presence of claudication was associated with an independent 2-fold increase in the combined end point of death or nonfatal cardiac event (38.5% vs 17.8%, P =.001) and a 5-fold increase in cardiac mortality (19.2% vs 3.6%, P =.001). Patients with intermittent claudication who were not treated with beta-blockers had a significant 3-fold mortality excess relative to those receiving beta-blockers. CONCLUSIONS Following myocardial infarction, the added presence of intermittent claudication is associated with heightened procoagulant and proinflammatory states and an underuse of beta-blocker therapy and is a strong independent predictor of recurrent cardiovascular events.
Collapse
Affiliation(s)
- Craig R Narins
- Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA. Thrombogenic Factors and Recurrent Coronary Events (THROMBO) Investigators
| | | | | | | | | | | | | |
Collapse
|
48
|
Harb TS, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rifai N, Miller Watelet LF, Arora R, Brown MW, Case RB, Dwyer EM, Gillespie JA, Goldstein RE, Greenberg H, Hochman J, Krone RJ, Liang CS, Lichstein E, Little W, Marcus FI, Oakes D, Sparks CE, VanVoorhees L. Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. Am J Cardiol 2002; 89:216-21. [PMID: 11792346 DOI: 10.1016/s0002-9149(01)02204-4] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Tareq S Harb
- Cardiology Unit of the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
Labor and delivery are associated with significant hemodynamic changes, as well as pain and anxiety, all of which could be fertile ground for arrhythmias. In order to establish whether cardiac arrhythmias occur more frequently during labor and delivery in healthy parturients and whether it clinically affects the mother or the newborn, 100 pregnant women admitted for delivery had Holter monitoring before, during, and up to 1 h postpartum. Our results show that, excluding sinus rhythm variations, only a slight majority of the study subjects had arrhythmia at all, while only 2% had more complex arrhythmias, none of which required any therapeutic intervention. We conclude that cardiac arrhythmias occurring during labor, delivery, and postpartum in the healthy parturient are no more frequent than in the general female population of the same age and are without clinical consequences for the mother and the newborn.
Collapse
Affiliation(s)
- R Berlinerblau
- Department of Internal Medicine, Maimonides Medical Center, Brooklyn, NY 11230, USA
| | | | | | | | | | | |
Collapse
|
50
|
Lichstein E. Exercise in the geriatric population. Am J Geriatr Cardiol 2001; 10:243-4. [PMID: 11528281 DOI: 10.1111/j.1076-7460.2001.00772.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- E Lichstein
- Department of Medicine, Maimonides Medical Center, State University of New York Health Science Center, Brooklyn, NY, USA
| |
Collapse
|